Metastatic castration-resistant prostate cancer: Critical review of enzalutamide

Clinical Medicine Insights: Oncology

Volumn 7, Issue , 2013, Pages 235-245

  El Amm, Joelle ^a   Patel, Nihar ^a   Freeman, Ashley ^a   Aragon Ching, Jeanny B ^a  

^a GEORGE WASHINGTON UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

Androgen receptor; Enzalutamide; MDV30; Metastatic castrate resistant prostate cancer

Indexed keywords

ABIRATERONE ACETATE; ANDROGEN RECEPTOR; ANTIANDROGEN; BICALUTAMIDE; CABAZITAXEL; DOCETAXEL; DUTASTERIDE; ENZALUTAMIDE; FLUTAMIDE; GEMFIBROZIL; GLUCOCORTICOID; ITRACONAZOLE; LEUPRORELIN; MDV 300; MITOXANTRONE; PLACEBO; PROSTATE SPECIFIC ANTIGEN; UNCLASSIFIED DRUG;

ADJUVANT THERAPY; ANTIANDROGEN THERAPY; ANTINEOPLASTIC ACTIVITY; ANXIETY; ARTHRALGIA; ASTHENIA; BACKACHE; BONE DISEASE; CANCER CHEMOTHERAPY; CANCER RESISTANCE; CANCER SURVIVAL; CASTRATION RESISTANT PROSTATE CANCER; CAUDA EQUINA SYNDROME; DIARRHEA; DIZZINESS; DRUG ABSORPTION; DRUG ANTAGONISM; DRUG APPROVAL; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG EFFICACY; DRUG ELIMINATION; DRUG HALF LIFE; DRUG INDUCED HEADACHE; DRUG MECHANISM; DRUG METABOLISM; DRUG RESPONSE; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; FATIGUE; FOOD AND DRUG ADMINISTRATION; HEMATURIA; HOT FLUSH; HUMAN; HYPERTENSION; INSOMNIA; MAXIMUM PLASMA CONCENTRATION; METASTASIS POTENTIAL; MUSCLE WEAKNESS; MUSCULOSKELETAL PAIN; NONHUMAN; OVERALL SURVIVAL; PARESTHESIA; PATIENT PREFERENCE; PERIPHERAL EDEMA; PROGRESSION FREE SURVIVAL; PROSTATE CANCER; PROSTATECTOMY; RECEPTOR AFFINITY; RESPIRATORY TRACT INFECTION; REVIEW; SEIZURE; SIDE EFFECT; SINGLE DRUG DOSE; SPINAL CORD COMPRESSION; TIME TO MAXIMUM PLASMA CONCENTRATION;

EID: 84882781061     PISSN: 11795549     EISSN: 11795549     Source Type: Journal    
DOI: 10.4137/CMO.S11670     Document Type: Review

References (55)

1. Siegel R, Naishadham D, Jemal A. Cancer statistics, 2013. CA Cancer J Clin. 2013;63(1):11-30.
2. Huggins C, Hodges CV. Studies on prostatic cancer. I. The effect of castration, of estrogen and androgen injection on serum phosphatases in metastatic carcinoma of the prostate. CA Cancer J Clin. 1972;22(4): 232-40.
3. Ryan CJ, Smith A, Lal P, et al. Persistent prostate-specific antigen expression after neoadjuvant androgen depletion: an early predictor of relapse or incomplete androgen suppression. Urology. 2006;68(4):834-9.
4. Sharifi N, Gulley JL, Dahut WL. Androgen deprivation therapy for prostate cancer. JAMA. 2005;294(2):238-44.
5. Sharifi N, Dahut WL, Figg WD. Secondary hormonal therapy for prostate cancer: what lies on the horizon? BJU Int. 2008;101(3):271-4.
6. Petrylak DP, Tangen CM, Hussain MH, et al. Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer. N Engl J Med. 2004;351(15):1513-20.
7. Tannock IF, de Wit R, Berry WR, et al; TAX 327 Investigators. Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer. N Engl J Med. 2004;351(15):1502-12.
8. Berthold DR, Pond GR, Soban F, de Wit R, Eisenberger M, Tannock IF. Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer: updated survival in the TAX 327 study. J Clin Oncol. 2008;26(2):242-5.
9. Schweizer MT, Antonarakis ES. Abiraterone and other novel androgendirected strategies for the treatment of prostate cancer: a new era of hormonal therapies is born. Ther Adv Urol. 2012;4(4):167-78.
10. de Bono JS, Oudard S, Ozguroglu M, et al. TROPIC Investigators. Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial. Lancet. 2010;376(9747):1147-54.
11. Attard G, Belldegrun AS, de Bono JS. Selective blockade of androgenic steroid synthesis by novel lyase inhibitors as a therapeutic strategy for treating metastatic prostate cancer. BJU Int. 2005;96(9):1241-6.
12. de Bono JS, Logothetis CJ, Molina A, et al; COU-AA-301 Investigators. Abiraterone and increased survival in metastatic prostate cancer. N Engl J Med. 2011;364(21):1995-2005.
13. Gelmann EP. Molecular biology of the androgen receptor. J Clin Oncol. 2002;20(13):3001-15.
14. Sharifi N. Hormonal therapy for prostate cancer: toward further unraveling of androgen receptor function. Anticancer Agents Med Chem. 2009;9(10): 1046-51.
15. Labrie F, Dupont A, Belanger A, et al. New approach in the treatment of prostate cancer: complete instead of partial withdrawal of androgens. Prostate. 1983;4(6):579-94.
16. Samson DJ, Seidenfeld J, Schmitt B, et al. Systematic review and metaanalysis of monotherapy compared with combined androgen blockade for patients with advanced prostate carcinoma. Cancer. 2002;95(2): 361-76.
17. Scher HI, Kolvenbag GJ. The antiandrogen withdrawal syndrome in relapsed prostate cancer. Eur Urol. 1997;31 Suppl 2:3-7; discussion 24-7.
18. Chen CD, Welsbie DS, Tran C, et al. Molecular determinants of resistance to antiandrogen therapy. Nat Med. 2004;10(1):33-9.
19. Jung ME, Ouk S, Yoo D, et al. Structure-activity relationship for thiohydantoin androgen receptor antagonists for castration-resistant prostate cancer (CRPC). J Med Chem. 2010;53(7):2779-96.
20. Tran C, Ouk S, Clegg NJ, et al. Development of a second-generation antiandrogen for treatment of advanced prostate cancer. Science. 2009;324(5928): 787-90.
21. Guerrero J, Alfaro IE, Gómez F, Protter AA, Bernales S. Enzalutamide, an androgen receptor signaling inhibitor, induces tumor regression in a mouse model of castration-resistant prostate cancer. Prostate. 2013;73(12): 1291-305.
22. Scher HI, Beer TM, Higano CS, et al; Prostate Cancer Foundation/ Department of Defense Prostate Cancer Clinical Trials Consortium. Antitumour activity of MDV3100 in castration-resistant prostate cancer: a phase 1-2 study. Lancet. 2010;375(9724):1437-46.
23. Xtandi [Package Insert]. Northbrook, IL: Astellas Pharma US, Inc. Available from: http://www.astellas.us/docs/12A005-ENZ-WPI.PDF. Accessed Jun 29, 2013.
24. Fosså SD, Slee PH, Brausi M, et al. Flutamide versus prednisone in patients with prostate cancer symptomatically progressing after androgen-ablative therapy: a phase III study of the European organization for research and treatment of cancer genitourinary group. J Clin Oncol. 2001;19(1):62-71.
25. Akaza H, Hinotsu S, Usami M, et al. Study Group for the Combined Androgen Blockade Therapy of Prostate Cancer. Combined androgen blockade with bicalutamide for advanced prostate cancer: long-term follow-up of a phase 3, double-blind, randomized study for survival. Cancer. 2009;115(15): 3437-45.
26. Crawford ED, Eisenberger MA, McLeod DG, et al. A controlled trial of leuprolide with and without flutamide in prostatic carcinoma. N Engl J Med. 1989;321(7):419-24.
27. Kolvenbag GJ, Furr BJ, Blackledge GR. Receptor affinity and potency of non-steroidal antiandrogens: translation of preclinical findings into clinical activity. Prostate Cancer Prostatic Dis. 1998;1(6):307-14.
28. Higano CS, Beer TM, Taplin M, et al. Antitumor activity of MDV3100 in preand post-docetaxel advanced prostate cancer: long-term follow-up of a phase I/II study. J Clin Oncol. 2011;29(Suppl 7):Abstr 134.
29. Scher HI, Halabi S, Tannock I, et al; Prostate Cancer Clinical Trials Working Group. Design and end points of clinical trials for patients with progressive prostate cancer and castrate levels of testosterone: recommendations of the Prostate Cancer Clinical Trials Working Group. J Clin Oncol. 2008;26(7): 1148-59.
30. Scher HI, Fizazi K, Saad F, et al; AFFIRM Investigators. Increased survival with enzalutamide in prostate cancer after chemotherapy. N Engl J Med. 2012;367(13):1187-97.
31. Miller K, Scher HI, Fizazi K, et al. Effect of enzalutamide on health-related quality of life (HRQoL) in men with metastatic castration-resistant prostate cancer (mCRPC) following docetaxel-based therapy: results from the AFFIRM study. ASCO Meeting Abstracts. 2013;31(Suppl 6):Abstr 17.
32. Scher H, Fizazi K, Saad F, et al. Association of baseline corticosteroid with outcomes in a multivariate analysis of the Phase 3 AFFIRM study of Enzalutamide (ENZA), an androgen receptor signaling inhibitor (ARSI). Ann Oncol. 2012;23(Suppl 9):Abstr 899PD.
33. Scher HI, Fizazi K, Saad F, et al. Impact of on-study corticosteroid use on efficacy and safety in the phase III AFFIRM study of enzalutamide (ENZA), an androgen receptor inhibitor. J Clin Oncol. 2013;31(Suppl 6):Abstr 6.
34. Montgomery RB, Kheoh TS, Molina A, et al. Effect of corticosteroid (CS) use at baseline (CUB) on overall survival (OS) in patients (pts) receiving abiraterone acetate (AA): Results from a randomized study (COU-AA-301) in metastatic castration-resistant prostate cancer (mCRPC) post-docetaxel (D). J Clin Oncol. 2013;31(Suppl):Abstr 5014.
35. Tombal B, Borre M, Rathenborg P, et al. Enzalutamide monotherapy: Phase II study results in patients with hormone-naive prostate cancer. J Clin Oncol. 2013;31(Suppl 6):Abstr 18.
36. Smith MR, Borre M, Rathenborg P, et al. Efficacy and safety of enzalutamide (ENZA) monotherapy in hormone-naive prostate cancer (HNPC). J Clin Oncol. 2013;31(Suppl):Abstr 5001.
37. Fleming MT, Rathkopf DE, Gibbons J, et al. Enzalutamide in combination with docetaxel in men with prostate cancer (PC): preliminary results from a phase I study. J Clin Oncol. 2013;31(Suppl 6):Abstr 63.
38. Kantoff PW, Higano CS, Shore ND, et al; IMPACT Study Investigators. Sipuleucel-T immunotherapy for castration-resistant prostate cancer. N Engl J Med. 2010;363(5):411-22.
39. Gravis G, Fizazi K, Joly F, et al. Androgen-deprivation therapy alone or with docetaxel in non-castrate metastatic prostate cancer (GETUG-AFU 15): a randomised, open-label, phase 3 trial. Lancet Oncol. 2013;14(2):149-58.
40. Parker C, Nilsson S, Heinrich D, et al. Updated analysis of the phase III, double-blind, randomized, multinational study of radium-223 chloride in castration-resistant prostate cancer (CRPC) patients with bone metastases (ALSYMPCA). J Clin Oncol. 2012;30(Suppl 18):LBA4512.
41. Aragon-Ching JB. Is there an optimal treatment sequencing strategy for metastatic castration-resistant prostate cancer? Future Oncol. 2013;9(5): 619-22.
42. Cookson MS, Roth BJ, Dahm P, et al. Castration-resistant prostate cancer: AUA guideline. J Urol. 2013;190(2):429-38.
43. Choudhury AD, Kantoff PW. New agents in metastatic prostate cancer. J Natl Compr Canc Netw. 2012;10(11):1403-9.
44. Kantoff PW, Mohler JL. New developments in the management of prostate cancer. J Natl Compr Canc Netw. 2013;11(Suppl 5):653-7.
45. Noonan KL, North S, Bitting RL, Armstrong AJ, Ellard SL, Chi KN. Clinical activity of abiraterone acetate in patients with metastatic castration-resistant prostate cancer progressing after enzalutamide. Ann Oncol. 2013;24(7): 1802-7.
46. Loriot Y, Bianchini D, Ileana E, et al. Antitumour activity of abiraterone acetate against metastatic castration-resistant prostate cancer progressing after docetaxel and enzalutamide (MDV3100). Ann Oncol. 2013;24(7): 1807-12.
47. Aragon-Ching JB. Enzalutamide (formerly MDV3100) as a new t{stroke}herapeutic option for men with metastatic castration-resistant prostate cancer. Asian J Androl. 2012;14(6):805-6.
48. Yuan X, Cai C, Chen S, Yu Z, Balk SP. Androgen receptor functions in castration-resistant prostate cancer and mechanisms of resistance to new agents targeting the androgen axis. Oncogene. Epub Jun 10, 2013.
49. Hu R, Lu C, Mostaghel EA, et al. Distinct transcriptional programs mediated by the ligand-dependent full-length androgen receptor and its splice variants in castration-resistant prostate cancer. Cancer Res. 2012;72(14):3457-62.
50. Li Y, Chan SC, Brand LJ, Hwang TH, Silverstein KA, Dehm SM. Androgen receptor splice variants mediate enzalutamide resistance in castration-resistant prostate cancer cell lines. Cancer Res. 2013;73(2):483-9.
51. McCourt C, Maxwell P, Mazzucchelli R, et al. Elevation of c-FLIP in castrateresistant prostate cancer antagonizes therapeutic response to androgen receptor-targeted therapy. Clin Cancer Res. 2012;18(14):3822-33.
52. Joseph JD, Lu N, Qian J, et al. A clinically relevant androgen receptor mutation confers resistance to 2nd generation anti-androgens enzalutamide and ARN-509. Cancer Discov. Epub Jun 18, 2013.
53. Balbas MD, Evans MJ, Hosfield DJ, et al. Overcoming mutation-based resistance to antiandrogens with rational drug design. Elife. 2013;2: e00499.
54. Ryan CJ, Li J, Kheoh T, Scher HI, Molina A. Baseline serum adrenal androgens are prognostic and predictive of overall survival (OS) in patients (pts) with metastatic castrate-resistant prostate cancer (mCRPC): Results of the COU-AA-301 phase 3 randomized trial. Cancer Res. 2012;72(8):AM2012-LB-434.
55. Attard G, De Bono JS, Li W, et al. ERG rearrangements and association with clinical outcome in patients (pts) receiving abiraterone acetate (AA): results from the COU-AA-302 study in chemotherapy (chemo)-naïve metastatic castration-resistant prostate cancer (mCRPC). J Clin Oncol. 2013;31(Suppl):Abstr 5004.